ADXN

Addex Therapeutics
ADXN

Market Cap: 8.55M

About: Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.

Employees: 23

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

0

News positive %

of 4 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

0.09% less ownership

Funds ownership: 0.09% [Q4 2023] → 0% (-0.09%) [Q1 2024]

67% less funds holding

Funds holding: 3 [Q4 2023] → 1 (-2) [Q1 2024]

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

99% less capital invested

Capital invested by funds: $717K [Q4 2023] → $4.99K (-$712K) [Q1 2024]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for ADXN.

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about ADXN published over the past 30 days

Addex's Partner Discontinues ADX71149 development in Epilepsy

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its partner Janssen Pharmaceuticals, Inc. (now known as J&J Innovative Medicine) has informed the company that it has discontinued development of ADX71149 (JNJ-40411813) in epilepsy.

Addex's Partner Discontinues ADX71149 development in Epilepsy

Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that positive results from the Company's novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) chronic cough program will be presented during the Thirteenth London International Cough Symposium (13th LICS) on July 19 and an abstract is available to conference participants on-line from today.

Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)

Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)

Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that Mikhail Kalinichev, Head of Translational Science, will present at the Thirteenth London International Cough Symposium taking place July 18 - 19, 2024 at Imperial College in London, U.K.

Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)

Addex Shareholders Approve All Resolutions at Annual General Meeting

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 1, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all proposals of the board of directors in its 2024 Annual General Meeting (AGM).

Addex Shareholders Approve All Resolutions at Annual General Meeting

Addex Therapeutics Ltd (ADXN) Q1 2024 Earnings Call Transcript

Addex Therapeutics Ltd (NASDAQ:ADXN ) Q1 2024 Earnings Conference Call June 6, 2024 10:00 AM ET Company Participants Tim Dyer - Chief Executive Officer Misha Kalinichev - Head, Translational Science Conference Call Participants Leonildo Delgado - Baader Helvea Operator Good day, and thank you for standing by. Welcome to the Addex Therapeutics First Quarter 2024 Financial Results and Corporate Update Conference Call.

Addex Therapeutics Ltd (ADXN) Q1 2024 Earnings Call Transcript

Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update

● GABAB PAM: Selection of drug candidates under Indivior collaboration expected by end of Q2 2024 .

Addex Therapeutics Reports Q1 2024 Financial Results and Provides Corporate Update

Addex Convenes Annual General Meeting 2024

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2024 Annual General Meeting will take place on Friday June 28, 2024, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am).

Addex Convenes Annual General Meeting 2024

Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024

Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it will issue its Q1 2024 Financial Results on June 6, 2024. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.

Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024

Addex to Present at Bio€quity Europe 2024

Geneva, Switzerland, May 8, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Bio€quity Europe 2024 conference taking place May 12 - 14, 2024 at the Kursaal Congress Center in San Sebastián, Spain.

Addex to Present at Bio€quity Europe 2024

Addex Provides Update on ADX71149 Phase 2 Epilepsy Study

Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced top-line data from a Phase 2 epilepsy study evaluating adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam.

Addex Provides Update on ADX71149 Phase 2 Epilepsy Study

See News Rankings